212 related articles for article (PubMed ID: 31005287)
1. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gore M; Hackshaw A; Brady WE; Penson RT; Zaino R; McCluggage WG; Ganesan R; Wilkinson N; Perren T; Montes A; Summers J; Lord R; Dark G; Rustin G; Mackean M; Reed N; Kehoe S; Frumovitz M; Christensen H; Feeney A; Ledermann J; Gershenson DM
Gynecol Oncol; 2019 Jun; 153(3):541-548. PubMed ID: 31005287
[TBL] [Abstract][Full Text] [Related]
2. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
Blagden SP; Cook AD; Poole C; Howells L; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; James EC; White IR; Perren T; Lord R; Dark G; Earl HM; Hall M; Kaplan R; Ledermann JA; Clamp AR
Lancet Oncol; 2020 Jul; 21(7):969-977. PubMed ID: 32615110
[TBL] [Abstract][Full Text] [Related]
3. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Alvarez Secord A; Bell Burdett K; Owzar K; Tritchler D; Sibley AB; Liu Y; Starr MD; Brady JC; Lankes HA; Hurwitz HI; Mannel RS; Tewari KS; O'Malley DM; Gray H; Bakkum-Gamez JN; Fujiwara K; Boente M; Deng W; Burger RA; Birrer MJ; Nixon AB
Clin Cancer Res; 2020 Mar; 26(6):1288-1296. PubMed ID: 31919136
[TBL] [Abstract][Full Text] [Related]
4. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Heitz F; Marth C; Henry S; Reuss A; Cibula D; Gaba Garcia L; Colombo N; Schmalfeld B; de Gregorio N; Wimberger P; Hasenburg A; Sehouli J; Gropp-Meier M; Schouten PC; Hahnen E; Hauke J; Polleis S; Harter P
Int J Gynecol Cancer; 2023 Dec; 33(12):1966-1969. PubMed ID: 37935524
[TBL] [Abstract][Full Text] [Related]
5. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B; Purdy C; Copeland LJ; Swisher EM; Bookman MA; Fleming G; Coleman R; Randall LM; Tewari KS; Monk BJ; Mannel RS; Walker JL; Cappuccini F; Cohn D; Muzaffar M; Mutch D; Wahner-Hendrickson A; Martin L; Colomban O; Burger RA
J Clin Oncol; 2022 Dec; 40(34):3965-3974. PubMed ID: 36252167
[TBL] [Abstract][Full Text] [Related]
6. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.
Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
[TBL] [Abstract][Full Text] [Related]
7. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
González Martín A; Oza AM; Embleton AC; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Bertrand MA; Beale P; Cervantes A; Kent E; Kaplan RS; Parmar MKB; Scotto N; Perren TJ;
Gynecol Oncol; 2019 Jan; 152(1):53-60. PubMed ID: 30449719
[TBL] [Abstract][Full Text] [Related]
8. A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.
Cohn DE; Barnett JC; Wenzel L; Monk BJ; Burger RA; Straughn JM; Myers ER; Havrilesky LJ
Gynecol Oncol; 2015 Feb; 136(2):293-9. PubMed ID: 25449568
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Kurtz JE; Pujade-Lauraine E; Oaknin A; Belin L; Leitner K; Cibula D; Denys H; Rosengarten O; Rodrigues M; de Gregorio N; Martinez García J; Petru E; Kocián R; Vergote I; Pautier P; Schmalfeldt B; Gaba L; Polterauer S; Mouret Reynier MA; Sehouli J; Churruca C; Selle F; Joly F; D'Hondt V; Bultot-Boissier É; Lebreton C; Lotz JP; Largillier R; Heudel PE; Heitz F;
J Clin Oncol; 2023 Oct; 41(30):4768-4778. PubMed ID: 37643382
[TBL] [Abstract][Full Text] [Related]
10. Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Arend RC; Monk BJ; Shapira-Frommer R; Haggerty AF; Alvarez EA; Amit A; Alvarez Secord A; Muller C; Casado Herraez A; Herzog TJ; Tewari KS; Cohen JG; Huang M; Yachnin A; Holeman LL; Ledermann JA; Rachmilewitz Minei T; Buyse M; Fain Shmueli S; Lavi M; Harats D; Penson RT;
J Clin Oncol; 2024 Jan; 42(2):170-179. PubMed ID: 37906726
[TBL] [Abstract][Full Text] [Related]
11. Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.
Wade KNS; Brady MF; Thai T; Wang Y; Zheng B; Salani R; Tewari KS; Gray HJ; Bakkum-Gamez JN; Burger RA; Moore KN; Bookman MA
Gynecol Oncol; 2019 Oct; 155(1):69-74. PubMed ID: 31409486
[TBL] [Abstract][Full Text] [Related]
12. Low-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective study.
Demirkiran A; Eryilmaz MK; Karaagac M; Araz M; Korkmaz M; Koçak MZ; Artac M
J Cancer Res Ther; 2023; 19(3):595-600. PubMed ID: 37470581
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Havrilesky LJ; Secord AA; Darcy KM; Armstrong DK; Kulasingam S;
J Clin Oncol; 2008 Sep; 26(25):4144-50. PubMed ID: 18757328
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S; Giannone G; Clamp AR; Ennis DP; Glasspool RM; Herbertson R; Krell J; Riisnaes R; Mirza HB; Cheng Z; McDermott J; Green C; Kristeleit RS; George A; Gourley C; Lewsley LA; Rai D; Banerji U; Hinsley S; McNeish IA
JAMA Oncol; 2023 May; 9(5):675-682. PubMed ID: 36928279
[TBL] [Abstract][Full Text] [Related]
15. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer.
Khanmammadov NJ; Doğan İ; Okay NS; Azizy A; Saip P; Aydiner A
Medicine (Baltimore); 2024 Jan; 103(1):e36750. PubMed ID: 38181291
[TBL] [Abstract][Full Text] [Related]
17. Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma.
Kurnit KC; Sinno AK; Fellman BM; Varghese A; Stone R; Sood AK; Gershenson DM; Schmeler KM; Malpica A; Fader AN; Frumovitz M
Obstet Gynecol; 2019 Dec; 134(6):1253-1259. PubMed ID: 31764736
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Haunschild CE; Tewari KS
Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
[TBL] [Abstract][Full Text] [Related]
19. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Pignata S; Bookman M; Sehouli J; Miller A; Penson RT; Taskiran C; Anderson C; Hietanen S; Myers T; Madry R; Willmott L; Lortholary A; Thomes-Pepin J; Aghajanian C; McCourt C; Stuckey A; Wu X; Nishio S; Copeland LJ; He Y; Molinero L; Patel S; Lin YG; Khor VK; Moore KN
Gynecol Oncol; 2023 Oct; 177():20-31. PubMed ID: 37625235
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.
Kahn RM; Ragupathi G; Zhou QC; Iasonos A; Kravetz S; Hensley ML; Konner JA; Makker V; Tew WP; Aghajanian C; Sabbatini PJ; O'Cearbhaill RE
Cancer Immunol Immunother; 2023 Jan; 72(1):183-191. PubMed ID: 35779095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]